The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Drugs working for Hikma Pharma as shares propelled higher by rating upgrades from both Citigroup and Jefferies 11:53 15 Mar 2018 Analysts at Citigroup upgraded their stance on the generic drugs group to �buy� from �neutral� with a new price target of 1,250p
A bid.......
1628 looks reasonable now... in two legs
Bid looming here maybe - why all this action - does the city know something? a 60% premium from here would still be cheap - and a lot would accept it????? CEO from - seems more than just a pop.......
If I was I wish I would listen to my own advice, i'm up to my neck in the dog UKOG. I didn't expect this to push through 1110 but it shot through like a bullet and the R3 on the daily pivot point
personal financial adviser arrives!
It's good to take profit where you can. You can alway buy back in later.
Good rise today, I think the profit taking will start before close.
There's no uncertainty now. Everyone knows the situation with Hikma and it's a lot more positive than it was before. I believe we will see a sustained recovery on the SP until it reaches about 1300 to 1400. That's why we haven't seen much evidence of profit taking today.
Well, it really was easy money buying in the 820p's +....crazy sale prices ....1100p is value ...debt well under control, dividend maintained, generics written off for now, with upswing possible in couple of years time... All to play for
Good to read that you have kept faith Aamir... I hope you recover to positive territory soon.
It seems this time recovery is on the solid ground unlike jump on CEO news and went back...
I was watching every day this forum just quite and realized to keep patience for a long time to recover but seems, I don't need to wait for that long... I did not lose the hope and did not sold but still need another 35% up to reach my breakeven... I hope SP will touch �15 at some point this year.
Good to see a turnaround at last... 1114 then a pullback to 960ish? Where's Aamir? Not heard from him recently.
sentiment is changing now.
It seems that Siggi is so impressed with Hikma's financial strength that he reckons that they can achieve growth by m&a on top of organic growth. No wonder the SP is flying this morning. I'm so glad i repurchased the shares i briefly sold yesterday to take advantage of the inevitable profit taking fall. Won't be doing so again for quite some time as this share is only on one path now.
Having advised selling Hikma back in August last year (which is when I should’ve heeded their advice!) they have now turned bullish on the company. Stating ‘trading on 14 times forward earnings, the shares are cheap for a global Pharma company. The generics industry is still tough, but with new management and more clarity on generic Advair, we think Hikma has reached a turning point. Upgrade to Buy.’ Time will tell but hopefully we have neared the bottom ready for a gentle rise back up.
Every single rally over the past 12 months has been sold into. This share will be testing 8.50 again by the end of March.
You're obviously a trading genius Foxywiki. But why didn't you just buy shares when they were available a few days ago at 850p? I have now bought back the shares i sold at £9.80 and these will be added to the ones i already held. No more trades on these because they a dividend is due soon and all the bad news is out the way. Now a great long term hold.
cant stick a paper profit in a wallet my friend. Maybe a lesson in trading and how to realise a profit and rinse and repeat.
LOL
Well done, Foxykiwi. I've also made �2k so far - by doing absolutely nothing!
and closed again.. Thats my �2k weekend wallet money. Im out for now so good luck holders.
I am crazy.. I just opened up a new short @�50pp
Sold 1000 shares at 980p but still hold 1650. I will buy these shares back once the profit takers bring the SP back down later today. Prospects for Hikma long term is good especially when Advair finally gets fda approval.